DIVISION OF CANCER SURVIVAL
NIH GRANTS
Fibroplate, Inc has developed a biological product that can
5. Mobilize the patient’s own stem cells to heal deep wounds
6. Stop internal and external bleeding related to low platelet count
7. Suppress pro-inflammatory cytokines (cell signals to other cells)
to accelerate healing
1. COMPLETED PROJECT:
“A Novel Agent to Manage Thrombocytopenic Patients with Platelet
Transfusion Refractoriness” NIH grant no. 1R43HL156324-01A1. Grant
period is 06/01/2021 to 07/31/2022. Now completed with excellent resulting
Fibroplate product can stop bleeding in patients with double deficits, that of
low platelet count and platelet-transfusion refractoriness. Results will be used
to support a Phase II grant application to NIH.
2. ONGOING PROJECT:
A new Phase I wound project titled “Fibrinogen coated albumin nanospheres
for mitigation of irradiation-induced wound healing impairment in breast
cancer patients” The project is designed to evaluate the effectiveness of FB
product in promoting healing of surgical wound after the harm done to tissues
from radiation therapy. This project will benefit breast cancer patients who
need radiation therapy to kill metastasized cancer cells even though the
radiation therapy will impede wound healing from the mastectomy, including
dehiscence of the surgical wound. Expected completion date: end of 2025.
3. NEW PROJECTS (GRANT APPLICATION SUBMITTED APRIL 2025)
“Protein Nanospheres to treat Renal Dysfunction”. A pilot study of this work
has been completed by Dr. Alex Lyubimov at the Center for Biomedical
Testing, Carlsbad, CA. The data showed great effectiveness of Fibroplate
product over kidney injury caused by a common chemotherapeutic agent called
Cisplatin.